Neurocords Overview
Neurocords is developing regenerative therapies for spinal cord injuries. Its focus is on a novel cellular therapy platform aimed at restoring function following spinal cord injuries.
Latest News
growth-positive
Orgenesis Inc. Announces Acquisition of Certain Neurocords LLC Assets, Strengthening its Regenerative Medicine Portfolio with Spinal Cord Injury Therapies
Orgenesis Inc., a global biotech company, announced the acquisition of Neurocords LLCs assets related to regenerative medicine therapies for spinal cord injuries. This strategic acquisition aims to expand access to cost-effective treatments by integrating Neurocords technology with Orgenesiss decentralized cell processing approach. The acquisition involves an equity transaction, with Orgenesis issuing 1,200,000 shares of common stock to Neurocords. Orgenesis plans to leverage its AI-based technology to enhance the production of autologous stem cells, potentially accelerating the development of transformative therapies for spinal cord injuries. The acquisition aligns with Orgenesiss mission to improve healthcare outcomes through innovative cell and gene therapies.
AcquisitionPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Acquired |
| Rounds | 0 |
| Investors | 0 |
Team Members
0
Employees: 0
Web & Social Links
Locations
HaRakevet St 58, Tel Aviv-Yafo, Israel
Photos & Videos
No files yet